Tag: Vivistim
Stroke survivors achieve long-term improvement in motor function with VNS therapy
Microtransponder has announced the publication of new findings in the journal Stroke validating the beneficial long-term outcomes of paired vagus nerve stimulation (VNS) therapy...
MicroTransponder secures US$65 million financing round to boost adoption of Vivistim...
MicroTransponder, a company that is attempting to transform the stroke continuum of care with its US Food and Drug Administration (FDA)-approved Vivistim paired vagus...
Ischaemic stroke outcomes with Vivistim paired VNS therapy highlighted at ISC...
Microtransponder has announced that neurosurgeon Ronald Benitez (Atlantic Brain and Spine, Morristown, USA) presented safety and outcomes data from the largest, real-world cohort of...
MicroTransponder raises US$53 million and appoints new CEO
MicroTransponder has closed an oversubscribed US$53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment firm. GPG Ventures and...
First commercial Vivistim patient set to begin paired vagus nerve stimulation...
MicroTransponder recently announced the first commercial use of its Vivistim paired vagus nerve stimulation (VNS) system for improved upper-limb function post-stroke. The company said...
MicroTransponder receives best new product award for Vivistim system
MicroTransponder today announced that its Vivistim paired vagus nerve stimulation (VNS) system has won the Neurotech Reports Gold Electrode Award for best new product. This announcement...
MicroTransponder gains FDA approval for first-of-its-kind VNS system to improve stroke...
MicroTransponder has announced US Food and Drug Administration (FDA) premarket approval of the Vivistim paired vagus nerve stimulation (VNS) system, which—according to a company...
